1[1]Moum B, Ekbom A, Vatn MH, et al. Clinical course during the 1 st year after diagnosis in ulcerative colitis and Crohn ' s disease. Results of a large, prospective population - based study in southeastern Norway, 1990 ～ 1993. Scand J Gatroenterol, 1997,32:1005 ～ 1012
2[2]Langholz E, Munkholm P, Davidsen M, et al. Course of ulcerative colitis: Analysis of changes in disease activity over years. Gastroenterology, 1994,107: 3 ～ 11
3[3]Feutren G, Mihatsch MJ. Risk factors for cyclosporine - induced nephropathy in patients with autoimmune diseases. International kidney biopsy registry of cyclosporine in autoimmune diseases. N Engl J Med, 1992,326:1654 ～ 1660
4[4]Lashner BA. Epidemiology of inflammatory bowel disease.Gatroenterol Clin North Am, 1995,24:467 ～ 474
5[5]The Mesalamine Study Group. An oral preparation of mesalamine as long - term maintenance therapy for ulcerative colitis. ( A randomized,placebo - controlled trial) Ann Intern Med, 1996,124:204 ～211
6[6]Sutherland LR, Martin F. 5 - Aminosalicylic acid enemas in treatment of distal ulcerative colitis and proctitis in Canada. Dig Dis Sci,1987,32 ( suppl. 12) :S64 ～ S66
7[7]Schroeder KW,Tremaine WJ,Ilstrup DM. Coated oral 5 - aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med, 1987,317:1625～ 1629
8[8]Misiewicz JJ,Lennard - Jones JE, Connell AM, et al. Controlled trial of sulphasalazine in maitenance therapy for ulcerative colitis. Lancet, 1965, i: 185 ～ 188
9[9]Azad Khan AK,Piris J, Truelove SC, et al. An optimum dose of sulfasalazine for maintenance treatment in ulcerative colitis.Gut, 1980,21:232 ～ 240
10[10]Sutherland L, Roth D, Beck P, et al. Oral 5 - aminosalicyclic acid for maintenance of remission in ulcerative colitis ( Cochrane Review). In: The Cochrane Library. Issue 4,2003. Chicester,UK:John Wiley & Sons, Ltd. Cochrane Database Syst Rev,2002 (4): CD000544
